Actively Recruiting
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Led by H. Lee Moffitt Cancer Center and Research Institute · Updated on 2026-04-01
100
Participants Needed
1
Research Sites
150 weeks
Total Duration
On this page
Sponsors
H
H. Lee Moffitt Cancer Center and Research Institute
Lead Sponsor
N
National Comprehensive Cancer Network
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.
CONDITIONS
Official Title
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with pathology-confirmed diagnosis of chronic lymphocytic leukemia
- Starting treatment with a Bruton's tyrosine kinase inhibitor, with or without an anti-CD 20 monoclonal antibody, or B-Cell Lymphoma 2 Protein Inhibitor combined with Obinutuzumab within 7 days
- Able to read and speak English or Spanish at an 8th grade level
You will not qualify if you...
- Patients with dementia
- Patients with traumatic brain injury
- Patients with central nervous system involvement of their leukemia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
Research Team
D
Daniel Lastorino
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here